Genovis Investor Relations » Press Releases

March 14, 2024 17:25 (CET) Carthesian Therapeutics terminates Genovis Licence Agreement Regulatory MAR

February 15, 2024 08:00 (CET) Year-end report January-December 2023 Regulatory MAR

February 13, 2024 08:20 (CET) Genovis to receive USD 1 million in milestone compensation related to the development of the Xork™ enzyme Regulatory

November 30, 2023 08:00 (CET) Genovis AB changes Certified Adviser to Carnegie Investment Bank AB (publ) Regulatory

November 15, 2023 08:00 (CET) Interim Report January-September 2023 Regulatory MAR

August 24, 2023 08:00 (CEST) Half-Yearly Report January-June 2023 Regulatory MAR

June 02, 2023 10:30 (CEST) Genovis launch Innovative IgM-Specific Protease with Wide-Ranging Applications in Life Science Markets Regulatory

May 16, 2023 18:33 (CEST) Communiqué from Genovis AB (publ) Annual General Meeting May 16, 2023 Regulatory

May 16, 2023 08:00 (CEST) Interim Report January-March 2023 Regulatory MAR

May 03, 2023 13:00 (CEST) Genovis and ArcticZymes Technologies enter into a collaboration agreement to accelerate growth in China Regulatory

Press Releases